Zydus Lifesciences concludes USFDA inspection at Ahmedabad facility with nil observations

Ahmedabad: Pharma major, Zydus Lifesciences Ltd., has announced that the group’s manufacturing facility at SEZ-2 located at Pharmez, Ahmedabad, underwent aUnited States Food and Drug Administration (USFDA) inspection from 2 nd July to 7 th July, 2023.

The Pre-Approval Inspection (PAI) closed with nil observations.

Medical Dialogues team had earlier reported thatthe Company had received the Establishment Inspection Report (EIR) from the USFDA for the inspection conducted at its manufacturing facility located at Pharmez, Ahmedabad, from March 20 to 24, 2023.

Read also:Zydus Lifesciences Gets EIR From USFDA For Pharmez Facility

Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian Pharmaceutical company headquartered in Ahmedabad. The Company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals. It is primarily engaged in the manufacture of generic drugs.

Read also: Zydus Lifesciences wins USFDA approval for Oxcarbazepine tablets to treat seizure disorders